Quidel Corporation

QuidelOrtho Reports Preliminary Revenue Results for Third Quarter 2022

Retrieved on: 
Wednesday, October 12, 2022
Medical Supplies, Health, Infectious Diseases, COVID-19, Pharmaceutical, Biotechnology, U.S. Securities and Exchange Commission, Interest, Transfusion medicine, Government, Webcast, Conference, Commission, Ortho Clinical Diagnostics, NASDAQ, Immunoassay, Security (finance), Nasdaq, Private Securities Litigation Reform Act, Automation, Knowledge, Company, IVD, Â, Nature, EDT, PDT, Quidel Corporation, Terminology, COVID-19, Medical device, Pharmaceutical industry, Online shopping

QuidelOrtho Corporation (NASDAQ: QDEL) (the Company or QuidelOrtho), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary revenue results for the third quarter ended October 2, 2022.

Key Points: 
  • QuidelOrtho Corporation (NASDAQ: QDEL) (the Company or QuidelOrtho), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary revenue results for the third quarter ended October 2, 2022.
  • The preliminary revenue results described herein are based on managements initial analysis for the third quarter ended October 2, 2022 and are subject to adjustments based on the Companys completion of its quarter end financial close process.
  • QuidelOrtho will report financial results for its third quarter 2022 after the market close on Wednesday, November 2, 2022.
  • Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PDT / 5:00 p.m. EDT to discuss the financial results.

Global Isothermal Nucleic Acid Amplification Technology Market Report (2022 to 2030) - Upsurge in Molecular Diagnostics is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, October 7, 2022
Infectious Diseases, General Health, Health, Adoption, Method, Infection, LAMP, Prevalence, HDA, Growth, Diagnosis, CAGR, Hepatitis, PCR, HIV, Vertically transmitted infection, Zika virus, Tuberculosis, Application, SDA, Awareness, NEAR, SPIA, Thermo Fisher Scientific, Lists of countries and territories, Quidel Corporation, COVID-19, USD, Vaccine, Technology

The global isothermal nucleic acid amplification technology market is expected to reach USD 10.7 billion by 2030, registering a CAGR of 12.3% during the forecast period, according to this report.

Key Points: 
  • The global isothermal nucleic acid amplification technology market is expected to reach USD 10.7 billion by 2030, registering a CAGR of 12.3% during the forecast period, according to this report.
  • A significant rise in awareness regarding the rapid testing and early detection of chronic and infectious diseases is expected to be a significant factor driving the market growth.
  • Moreover, isothermal amplification involves the use of less expensive procedures and equipment, which can fuel its adoption in developing countries.
  • Such product launches are favoring market growth by increasing the utility of INAAT techniques for a broad range of applications.

EQS-News: Development of New Drugs to Target Lyme and Other Infectious Diseases Subject of a New Webinar Now Available From Quidel Corporation

Retrieved on: 
Tuesday, October 4, 2022
Duke University School of Medicine, Howard Hughes Medical Institute, Tick-Borne Disease Alliance, Cancer, Physician, Obesity, Nasdaq, Research, School of Life Sciences (University of Dundee), Privacy, Prevalence, Blood, FDA, Infection, COVID-19, Borrelia burgdorferi, Method, University of Washington, Patient, Hypertension, University, Pharmacology, Vaccine, Pharmaceutical industry, Lyme disease, Quidel Corporation

It will also provide an overview as to the current antibiotics used for treating Lyme disease and explore how powerful new drugsnovel inhibitorscan selectively target Borrelia burgdorferi (the bacterium that causes Lyme disease).

Key Points: 
  • It will also provide an overview as to the current antibiotics used for treating Lyme disease and explore how powerful new drugsnovel inhibitorscan selectively target Borrelia burgdorferi (the bacterium that causes Lyme disease).
  • The webinar is PACE-accredited and sponsored in collaboration with Global Lyme Alliance.
  • Conducting the webinar is Timothy Haystead, Ph.D., professor of pharmacology and cancer biology at Duke University School of Medicine.
  • Quidel is the diagnostic health care manufacturer behind the industrys most rapid and reliable in-office test for Lyme disease, Sofia 2 Lyme FIA.

Development of New Drugs to Target Lyme and Other Infectious Diseases Subject of a New Webinar Now Available From Quidel Corporation

Retrieved on: 
Tuesday, October 4, 2022
Health, Infectious Diseases, Hospitals, Managed Care, General Health, Pharmaceutical, Biotechnology, Duke University School of Medicine, Howard Hughes Medical Institute, Tick-Borne Disease Alliance, Cancer, Physician, Obesity, Nasdaq, Research, School of Life Sciences (University of Dundee), Privacy, Prevalence, Blood, FDA, COVID-19, Infection, Borrelia burgdorferi, Method, University of Washington, Patient, Hypertension, University, Pharmacology, Vaccine, Pharmaceutical industry, Lyme disease, Quidel Corporation

It will also provide an overview as to the current antibiotics used for treating Lyme disease and explore how powerful new drugsnovel inhibitorscan selectively target Borrelia burgdorferi (the bacterium that causes Lyme disease).

Key Points: 
  • It will also provide an overview as to the current antibiotics used for treating Lyme disease and explore how powerful new drugsnovel inhibitorscan selectively target Borrelia burgdorferi (the bacterium that causes Lyme disease).
  • The webinar is PACE-accredited and sponsored in collaboration with Global Lyme Alliance.
  • Conducting the webinar is Timothy Haystead, Ph.D., professor of pharmacology and cancer biology at Duke University School of Medicine.
  • Quidel is the diagnostic health care manufacturer behind the industrys most rapid and reliable in-office test for Lyme disease, Sofia 2 Lyme FIA.

QuidelOrtho to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Retrieved on: 
Tuesday, September 6, 2022
Other Health, Research, General Health, Data Management, Medical Devices, Technology, Infectious Diseases, Health Technology, Science, Biotechnology, Other Science, Health, Morgan Stanley, Quidel Corporation, Conference, Ortho Clinical Diagnostics, Knowledge, Transfusion medicine, Automation, Immunoassay, Nasdaq, NASDAQ, Morgan, IVD, Medical device

QuidelOrtho Corporation (NASDAQ: QDEL) (QuidelOrtho), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Morgan Stanley 20th Annual Global Healthcare Conference in New York beginning on September 12, 2022, with a fireside chat scheduled for 4:50 p.m.

Key Points: 
  • QuidelOrtho Corporation (NASDAQ: QDEL) (QuidelOrtho), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Morgan Stanley 20th Annual Global Healthcare Conference in New York beginning on September 12, 2022, with a fireside chat scheduled for 4:50 p.m.
  • QuidelOrtho Corporation (Nasdaq: QDEL) unites the power of Quidel Corporation and Ortho Clinical Diagnostics behind a shared mission of developing and manufacturing innovative technologies that raise the performance of diagnostic testing and create better patient outcomes across the entire healthcare continuum.
  • Our companys comprehensive product portfolio delivers accuracy, speed, automation and access, providing critical information when and where it is needed most.
  • Inspired by a spirit of service, the QuidelOrtho family is committed to enhancing the well-being of people worldwide and happy in the knowledge we are making a difference.

Quidel and World Champion Los Angeles Rams Partner to Combat COVID-19 and Promote Health Awareness in the L.A. Community

Retrieved on: 
Thursday, September 1, 2022
Sports, General Health, Data Management, Medical Devices, Technology, Infectious Diseases, Football, Health Technology, COVID-19, Biotechnology, Medical Supplies, Health, Partnership, Quidel Corporation, COVID-19, CEO, NASDAQ, History of the Los Angeles Rams, Immunoassay, Corporation, IVD, Multimedia, COVID-19 testing, Partner, Television, Nasdaq, Ortho Clinical Diagnostics, Knowledge, Transfusion medicine, Automation, Health, Medical device, Rams

Quidel Corporation (Quidel), a subsidiary of QuidelOrtho Corporation (NASDAQ: QDEL) and a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and the World Champion Los Angeles Rams today announced a multi-year partnership agreement to promote health awareness and COVID-19 testing.

Key Points: 
  • Quidel Corporation (Quidel), a subsidiary of QuidelOrtho Corporation (NASDAQ: QDEL) and a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and the World Champion Los Angeles Rams today announced a multi-year partnership agreement to promote health awareness and COVID-19 testing.
  • The agreement makes Quidel an Official Partner of the Los Angeles Rams and designates Quidels QuickVue at-home rapid antigen test as the Official At-Home COVID Test of the Los Angeles Rams.
  • In addition, the partnership includes a variety of promotions and stadium activation initiatives as well as a presence at community programs across the greater Los Angeles area.
  • We look forward to teaming up to promote health awareness and the benefits of COVID-19 testing."

COVID-19 Will Be With Us For Years, So Will a Large In Vitro Diagnostics Market

Retrieved on: 
Wednesday, August 31, 2022
BD (company), COVID-19, Science, Cancer, HPV, Publication, Immunohistochemistry, Disease, Carlson, Alere, AACC, Cepheid variable, Abbott, Molecular Cancer Research, DNA, IVD, Infection, Multimedia, Yale University, Roche, Severe acute respiratory syndrome coronavirus 2, COVID-19 testing, PSAS, Yale Daily News, Non-functional testing, Siemens Healthineers, Risk, Diabetes, Terminology, POC, Acquisition, Industry, Growth, COVID, Patient, Fine chemical, Pharmaceutical industry, Vaccine, Medical device, Quidel Corporation, Kalorama

 ARLINGTON, Va., Aug. 31, 2022 /PRNewswire/ -- The worldwide in vitro diagnostic (IVD) market will reach $127.4 billion dollars in 2022, according to IVD market research firm Kalorama Information.  That's the finding from the firm's 15th large-scale IVD industry report, The Worldwide Market for In Vitro Diagnostic Tests, released this month. The market will grow to $140.1 billion in 2027, and COVID-19 testing will drive that market. The larger part of the IVD market is non-COVID testing and diabetes and cancer testing products, which will also drive the industry to growth.  

Key Points: 
  • That's the finding from the firm's 15th large-scale IVD industry report, The Worldwide Market for In Vitro Diagnostic Tests , released this month.
  • The market will grow to $140.1 billion in 2027, and COVID-19 testing will drive that market.
  • Kalorama has called the IVD market for two decades in detailed reports based on company financial information, interviews and medical statistics (FOR MORE INFORMATION: https://kaloramainformation.com/product/the-worldwide-market-for-in-vitr... ).
  • But the bulk of the market sales in 2022, an estimated $94.8 billion, will be from non-COVID-19 IVD tests.

Bacterial Biofilms, Responsible for Up to 75% of All Infectious Diseases in America, Explored in New Webinar From Quidel Corporation

Retrieved on: 
Wednesday, August 24, 2022
Technology, Infectious Diseases, Hospitals, Software, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Nervous system, COVID-19, University, Human, Exocrine gland, Mucus, Tick-Borne Disease Alliance, Biofilm, Disease, Virulence, Heart, National, Infection, Blood, Point-of-care testing, Tick-borne disease, Physician, Skin, Diagnosis, Degenerative disease, Time-invariant system, Laboratory, Gastrointestinal tract, Cystic fibrosis, Joint, Privacy, Nasdaq, FDA, Prevalence, Chronic Lyme disease, Â, Environment, Bacteria, Patient, Vaccine, Quidel Corporation, Lyme disease

This important medical reality is now being addressed in a new webinar made available by Quidel Corporation, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions.

Key Points: 
  • This important medical reality is now being addressed in a new webinar made available by Quidel Corporation, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions.
  • The webinar, available at https://education.quidel.com/educational-categories , discusses the basics of bacterial biofilms including when and how they develop, its composition and factors that contribute to antibiotic resistance and virulence.
  • The session also explores the biofilms in the context of Lyme disease and the potential link between chronic Lyme and biofilm formation.
  • It is important to understand how these biofilms are formed and their maturation as well as their dispersal.

Human Reproductive Technology Products and Global Markets Report 2022: Focus on 3 Major Areas - Infertility, Contraception, and Sexual Dysfunction - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 23, 2022
Medical Devices, Health, COVID-19, Merck Serono, Pandora, Female, Research, Culture, Sterilization, Reproductive health, Time, Reproduction, Lists of countries and territories, Male, Physician, Birth, Religion, Investment, Sexual dysfunction, Method, Bayer, Disorder, Condom, Social environment, Quidel Corporation, Medicine, Fertility, Abortion, Probability, FTC v. Actavis, Inc., ART, Infertility, Gaps, Woman, Acquisition, Growth, Industry, Patient, Creative industries, Birth control, Pharmaceutical industry, Fine chemical, Sildenafil

The "Human Reproductive Technologies: Products and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Human Reproductive Technologies: Products and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • Increasing investments and advancements in each of the three major areas of infertility, contraception, and sexual dysfunction.
  • The report is designed to be a comprehensive business tool to provide an in-depth look at the markets for reproductive drugs and technologies.
  • The report reviews male and female reproductive health, presents standard pharmaceutical treatments and devices, and reviews technologies associated with reproductive health.

Medical Device Innovation Consortium Launches Initiative to Improve Accuracy of Next Generation Sequencing-Based Cancer Diagnostics

Retrieved on: 
Monday, August 22, 2022
Medical Devices, FDA, Genetics, Health Technology, Biotechnology, Biometrics, Managed Care, Health, Oncology, Partnership, Co-leader of the Scottish Green Party, CEO, Cancer, Catalog, Safety, National Institute, Device, Grant, National Institute of Standards and Technology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Horizon Discovery, NIST, Food and Drug Administration, Doctor of Philosophy, FDA Center for Devices and Radiological Health, NGS, SRS, CRISPR, Food, Diagnosis, DNA, NIH, PerkinElmer, National, National Philanthropic Trust, National Institutes of Health, MD, MDIC, SRSS, Gordon, Center, FDA, Therapy, Industry, Data, Personalized medicine, Efficiency, Medical device, Pharmaceutical industry, Quidel Corporation, Technology, Illumina

The initiative also includes the goal to create a publicly available global genomic data resource library of datasets with the potential to be used by sponsors and regulators.

Key Points: 
  • The initiative also includes the goal to create a publicly available global genomic data resource library of datasets with the potential to be used by sponsors and regulators.
  • These diagnostic tests need to be validated for accurate clinical use, and reference samples are essential to the validation process.
  • But well-characterized and widely accepted reference materials do not exist for NGS-based diagnostics, complicating the development and validation process, said Andrew Fish, President and CEO, MDIC.
  • Founded in 2012, the Medical Device Innovation Consortium (MDIC) is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle.